Professor Dirk Eick and staff members of the Institute of Clinical Molecular Biology and Tumor Genetics of Helmholtz Zentrum München, together with colleagues from the University of Wisconsin-Madison, Wisconsin, USA, have now identified another piece in the puzzle of epigenetics: They showed that the enzyme TFIIH kinase is involved in epigenetic regulation.
The scientists were interested in the fine regulation of the cell nucleus enzyme RNA polymerase II. This transcribes the genetic information of the genetic substance DNA into messenger RNA - mRNA for short – which in turn is the basis for protein synthesis. At the same time RNA polymerase II is also responsible for the production of other kinds of RNA molecules, the so-called snRNA, which are not translated into proteins but take on other tasks. In prior research Eick and his colleagues had observed that a certain region of the RNA polymerase II enzyme – the carboxy-terminal domain – is involved in deciding which kinds of RNA are formed. In humans this domain consists of 52 repeats of a sequence of seven amino acids. For RNA synthesis the determining factor is whether and how specific amino acids of this region are modified biochemically. Thus, it is absolutely essential for the synthesis of snRNA that the amino acid serine at position 7 of this repeat sequence is provided with an additional phosphate group. If this is lacking, mRNA will be produced, but not any snRNA. The reason for that is presumably that this phosphorylation enables the interaction with a protein complex – the so-called integrator complex – which is necessary for snRNA formation. In other words, the modification of the enzyme RNA polymerase II at defined positions regulates whether this enzyme can produce certain kinds of RNA molecules or not.
In their latest research, the scientists led by Dirk Eick showed that the enzyme TFIIH kinase is responsible for the selective phosphorylation of RNA polymerase II. “With these findings another building block has been identified that plays a key role in epigenetic regulation by means of RNA polymerase II,” Professor Eick said. “This is of great significance because knowledge of epigenetic mechanisms is necessary in order to better understand cancer and other diseases and to be able to provide more targeted treatment.”
The Institute of Clinical Molecular Biology and Tumor Genetics of Helmholtz Zentrum München focuses on genetic alterations in the cell that arise during malignant transformation and are causally related to the development into a tumor cell. Besides gaining new insights for basic research, the main aim is to make advances in the therapy of malignant diseases and to develop vectors for gene therapy.
Helmholtz Zentrum München is the German Research Center for Environmental Health. As leading center oriented toward Environmental Health, it focuses on chronic and complex diseases which develop from the interaction of environmental factors and individual genetic disposition. Helmholtz Zentrum München has around 1680 staff members. The head office of the center is located in Neuherberg to the north of Munich on a 50-hectare research campus. Helmholtz Zentrum München belongs to the Helmholtz Association, Germany’s largest research organization, a community of 15 scientific-technical and medical-biological research centers with a total of 26,500 staff members.